300858 科拓生物
已收盘 04-30 15:00:00
资讯
新帖
简况
科拓生物涨5.21%,东吴证券四日前给出“买入”评级
证券之星 · 04-29
科拓生物涨5.21%,东吴证券四日前给出“买入”评级
科拓生物(300858)2024年一季报简析:净利润减7.66%,盈利能力上升
证券之星 · 04-26
科拓生物(300858)2024年一季报简析:净利润减7.66%,盈利能力上升
科拓生物(300858)3月31日股东户数0.96万户,较上期增加1.76%
证券之星 · 04-25
科拓生物(300858)3月31日股东户数0.96万户,较上期增加1.76%
图解科拓生物一季报:第一季度单季净利润同比减7.66%
证券之星 · 04-25
图解科拓生物一季报:第一季度单季净利润同比减7.66%
科拓生物最新公告:一季度净利润1851.6万元 同比下降7.66%
证券之星 · 04-24
科拓生物最新公告:一季度净利润1851.6万元 同比下降7.66%
4月24日科拓生物发布公告,其股东减持112.1万股
证券之星 · 04-24
4月24日科拓生物发布公告,其股东减持112.1万股
科拓生物(300858.SZ)发一季度业绩,净利润1851.6万元,同比减少7.66%
智通财经 · 04-24
科拓生物(300858.SZ)发一季度业绩,净利润1851.6万元,同比减少7.66%
科拓生物(300858.SZ)发2023年度业绩,净利润9347.99万元,同比减少14.93%
智通财经 · 04-24
科拓生物(300858.SZ)发2023年度业绩,净利润9347.99万元,同比减少14.93%
东吴证券:给予科拓生物买入评级
证券之星 · 04-23
东吴证券:给予科拓生物买入评级
加载更多
公司概况
公司名称:
北京科拓恒通生物技术股份有限公司
所属行业:
食品制造业
上市日期:
2020-07-27
主营业务:
北京科拓恒通生物技术股份有限公司的主营业务是从事复配食品添加剂、食用益生菌制品以及动植物微生态制剂研发、生产与销售。公司的主要产品分为食用益生菌原料菌粉、即食型复合益生菌固体饮料、发酵剂、生物保鲜剂、KY系列、MD系列、B系列、FL系列、FM系列、A系列、动物微生态制剂、植物微生态制剂。
发行价格:
23.70
{"stockData":{"symbol":"300858","market":"SZ","secType":"STK","nameCN":"科拓生物","latestPrice":16.88,"timestamp":1714460601000,"preClose":16.36,"halted":0,"volume":3681710,"delay":0,"floatShares":179000000,"shares":263000000,"eps":0.349,"marketStatus":"已收盘","marketStatusCode":5,"change":0.52,"latestTime":"04-30 15:00:00","open":16.51,"high":17.13,"low":16.24,"amount":61609300,"amplitude":0.0544,"askPrice":16.88,"askSize":108,"bidPrice":16.86,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.349,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":16.36,"symbolType":"stock","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":18,"lowLimit":14.72,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":263495118,"pbRate":2.46,"roa":"--","roe":"1.06%","epsLYR":0.35,"committee":0.13522,"marketValue":4448000000,"floatMarketCap":3021000000,"peRate":48.366761,"changeRate":0.0318,"turnoverRate":0.0206,"status":0},"requestUrl":"/m/hq/s/300858/","defaultTab":"news","newsList":[{"id":"2431883709","title":"科拓生物涨5.21%,东吴证券四日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431883709","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431883709?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:42","pubTimestamp":1714380179,"startTime":"0","endTime":"0","summary":"今日科拓生物涨5.21%,收盘报16.36元。2024年4月25日,东吴证券研究员孙瑜,周韵发布了对科拓生物的研报《2023年年报&2024年一季报点评:益生菌业务表现亮眼,加速战略转型》,该研报对科拓生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为78.73%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为东吴证券的孙瑜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900017750.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430263455","title":"科拓生物(300858)2024年一季报简析:净利润减7.66%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2430263455","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430263455?lang=zh_cn&edition=full","pubTime":"2024-04-26 06:27","pubTimestamp":1714084061,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期科拓生物发布2024年一季报。根据财报显示,本报告期中科拓生物净利润减7.66%,盈利能力上升。截至本报告期末,公司营业总收入5902.56万元,同比下降18.19%,归母净利润1851.64万元,同比下降7.66%。公司最新一期年度报表的现金流为正,经营性现金流和利润相匹配。重仓科拓生物的前十大基金见下表:持有科拓生物最多的基金为鹏华新兴产业混合,目前规模为28.61亿元,最新净值2.482,较上一交易日下跌0.52%,近一年下跌18.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600013949.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430476964","title":"科拓生物(300858)3月31日股东户数0.96万户,较上期增加1.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430476964","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430476964?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:19","pubTimestamp":1714036763,"startTime":"0","endTime":"0","summary":"证券之星消息,近日科拓生物披露,截至2024年3月31日公司股东户数为9560.0户,较12月31日增加165.0户,增幅为1.76%。在化学制品行业个股中,科拓生物股东户数低于行业平均水平,截至3月31日,化学制品行业平均股东户数为2.43万户。从股价来看,2023年12月31日至2024年3月31日,科拓生物区间跌幅为8.29%,在此期间股东户数增加165.0户,增幅为1.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500036131.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430461997","title":"图解科拓生物一季报:第一季度单季净利润同比减7.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430461997","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430461997?lang=zh_cn&edition=full","pubTime":"2024-04-25 01:38","pubTimestamp":1713980308,"startTime":"0","endTime":"0","summary":"证券之星消息,科拓生物2024年一季报显示,公司主营收入5902.56万元,同比下降18.19%;归母净利润1851.64万元,同比下降7.66%;扣非净利润1521.21万元,同比下降14.17%;负债率2.98%,投资收益28.02万元,财务费用-686.55万元,毛利率54.34%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500002314.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429437702","title":"科拓生物最新公告:一季度净利润1851.6万元 同比下降7.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429437702","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429437702?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:10","pubTimestamp":1713960622,"startTime":"0","endTime":"0","summary":"科拓生物公布第一季度报告,营业收入5902.56万元,同比下降18.19%,净利润1851.6万元,同比下降7.66%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400042659.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429988437","title":"4月24日科拓生物发布公告,其股东减持112.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429988437","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429988437?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:00","pubTimestamp":1713960052,"startTime":"0","endTime":"0","summary":"证券之星消息,4月24日科拓生物发布公告《科拓生物:关于股东减持计划期限届满的公告》,其股东张列兵于2023年8月24日至2024年4月24日间合计减持112.09万股,占公司目前总股本的0.4254%,变动期间该股股价下跌13.42%,截止4月24日收盘报15.1元。股东增减持详情见下表:根据科拓生物2023年三季报公布的十大股东详情如下:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400042231.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429325964","title":"科拓生物(300858.SZ)发一季度业绩,净利润1851.6万元,同比减少7.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429325964","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429325964?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:48","pubTimestamp":1713959299,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科拓生物(300858.SZ)发布2024年第一季度报告,营业收入5902.56万元,同比减少18.19%。归属于上市公司股东的净利润1851.6万元,同比减少7.66%。归属于上市公司股东的扣除非经常性损益的净利润1521.2万元,同比减少14.17%。基本每股收益0.07元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108965.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429432317","title":"科拓生物(300858.SZ)发2023年度业绩,净利润9347.99万元,同比减少14.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429432317","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429432317?lang=zh_cn&edition=full","pubTime":"2024-04-24 19:45","pubTimestamp":1713959126,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科拓生物(300858.SZ)发布2023年年度报告,营业收入2.99亿元,同比减少18.94%。归属于上市公司股东的净利润9347.99万元,同比减少14.93%。归属于上市公司股东的扣除非经常性损益的净利润8046万元,同比减少17.96%。基本每股收益0.35元,向全体股东每10股派发现金红利1.50元(含税),送红股0股(含税),以资本公积金向全体股东每10股转增0股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108958.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429316311","title":"东吴证券:给予科拓生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429316311","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429316311?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:51","pubTimestamp":1713862299,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司孙瑜,周韵近期对科拓生物进行研究并发布了研究报告《国产替代进行时,益生菌第一股加速转型》,本报告对科拓生物给出买入评级,当前股价为14.59元。最新盈利预测明细如下:该股最近90天内共有1家机构给出评级,买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300031343.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-27","address":"北京市怀柔区雁栖经济开发区牤牛河路31号院1号-2","stockEarnings":[{"period":"1week","weight":0.157},{"period":"1month","weight":-0.0463},{"period":"3month","weight":0.0144},{"period":"6month","weight":-0.1445},{"period":"1year","weight":-0.0449},{"period":"ytd","weight":-0.1254}],"companyName":"北京科拓恒通生物技术股份有限公司","boardCode":"AI0014","perCapita":"18722股","boardName":"食品制造业","registeredCapital":"26349万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":" 北京科拓恒通生物技术股份有限公司的主营业务是从事复配食品添加剂、食用益生菌制品以及动植物微生态制剂研发、生产与销售。公司的主要产品分为食用益生菌原料菌粉、即食型复合益生菌固体饮料、发酵剂、生物保鲜剂、KY系列、MD系列、B系列、FL系列、FM系列、A系列、动物微生态制剂、植物微生态制剂。","serverTime":1714925908428,"listedPrice":23.7,"stockholders":"9560人(较上一季度增加1.76%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科拓生物(300858)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科拓生物(300858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科拓生物,300858,科拓生物股票,科拓生物股票老虎,科拓生物股票老虎国际,科拓生物行情,科拓生物股票行情,科拓生物股价,科拓生物股市,科拓生物股票价格,科拓生物股票交易,科拓生物股票购买,科拓生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科拓生物(300858)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科拓生物(300858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}